CN108635569A - 一种小猪血清细胞营养液 - Google Patents

一种小猪血清细胞营养液 Download PDF

Info

Publication number
CN108635569A
CN108635569A CN201810610583.8A CN201810610583A CN108635569A CN 108635569 A CN108635569 A CN 108635569A CN 201810610583 A CN201810610583 A CN 201810610583A CN 108635569 A CN108635569 A CN 108635569A
Authority
CN
China
Prior art keywords
swine serum
cell
nutrient solution
small swine
small
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810610583.8A
Other languages
English (en)
Inventor
陈燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Zhengjiang Modern Biotechnology Co Ltd
Original Assignee
Tianjin Zhengjiang Modern Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Zhengjiang Modern Biotechnology Co Ltd filed Critical Tianjin Zhengjiang Modern Biotechnology Co Ltd
Priority to CN201810610583.8A priority Critical patent/CN108635569A/zh
Publication of CN108635569A publication Critical patent/CN108635569A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/983—Blood, e.g. plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本发明是一种小猪血清细胞营养液，包括小猪血清、表皮细胞生长因子和透明质酸；各成分的体积百分比为：小猪血清：65‑97％；表皮细胞生长因子：2‑15％；透明质酸：1‑30％。本发明所述的一种小猪血清细胞营养液，通过三种成分合理结合搭配，小猪血清细胞营养液在组织修复过程中科学地从细胞营养、生长、修复三方面对细胞进行全方位的维护和调节，达到缩短修复时间，加快皮肤修复的目的。

Description

一种小猪血清细胞营养液
技术领域
本发明涉及小猪血清细胞营养液领域，尤其涉及一种小猪血清细胞营养液。
背景技术
现有修复产品的主要成分为表皮细胞生长因子，表皮细胞生长因子对促进成纤维细胞的代谢和胶原蛋白的形成发挥着重要功能，能促进皮肤组织的生长繁殖，调控皮肤上皮，内皮和基质细胞的分裂、繁殖和生长分化，促进细胞代谢和生长。
由于表皮细胞生长因子只能单一起到细胞生长的作用，故用户在使用此类修复产品使用过程发现如下问题：1、修复和生长的周期相对较长。2、营养成分单一，局限性较大，不能满足用户的多种需求。
为此，设计一种小猪血清细胞营养液，解决以上问题。
发明内容
本发明为克服以上不足，提供一种小猪血清细胞营养液，包括小猪血清、表皮细胞生长因子和透明质酸；
各成分的体积百分比为：小猪血清：65-97％；表皮细胞生长因子：2-15％；透明质酸：1-30％。
小猪血清：富含70％无机物质，如电解质和多种必要微量元素，以及30％有机物质，如寡糖、核酸衍生物、氨基酸、低分子多肽、糖脂类及糖和类脂代谢的中间产物等，通过促进细胞对葡萄糖的摄取和利用，增加细胞对养的摄入和利用，从而使三磷酸腺苷生成增加，使细胞能量提高，在机能缺陷、代谢受抑制的情况下和能量需求增加时，在细胞水平促进细胞能量代谢、改善细胞功能、增强修复作用。
透明质酸：是一种高分子的聚合物，以其独特的分子结构和理化性质在机体中显示出调节蛋白质，水电解质扩散及运转，促进创伤愈合等，最重要的是玻尿酸具有特殊的保水作用，水为万物之源，透明质酸特有的保水功能在细胞修复过程中起到至关重要的作用。
本发明的有益效果是：
本发明所述的一种小猪血清细胞营养液，通过三种成分合理结合搭配，小猪血清细胞营养液在组织修复过程中科学地从细胞营养、生长、修复三方面对细胞进行全方位的维护和调节，达到缩短修复时间，加快皮肤修复的目的。
具体实施方式
以下将结合本发明的实施例进行详细叙述。
一种小猪血清细胞营养液，包括小猪血清、表皮细胞生长因子和透明质酸；
各成分的体积百分比为：小猪血清：65-97％；表皮细胞生长因子：2-15％；透明质酸：1-30％。
原理：
小猪血清：富含70％无机物质，如电解质和多种必要微量元素，以及30％有机物质，如寡糖、核酸衍生物、氨基酸、低分子多肽、糖脂类及糖和类脂代谢的中间产物等，通过促进细胞对葡萄糖的摄取和利用，增加细胞对养的摄入和利用，从而使三磷酸腺苷生成增加，使细胞能量提高，在机能缺陷、代谢受抑制的情况下和能量需求增加时，在细胞水平促进细胞能量代谢、改善细胞功能、增强修复作用。
透明质酸：是一种高分子的聚合物，以其独特的分子结构和理化性质在机体中显示出调节蛋白质，水电解质扩散及运转，促进创伤愈合等，最重要的是玻尿酸具有特殊的保水作用，水为万物之源，透明质酸特有的保水功能在细胞修复过程中起到至关重要的作用。
使用方法：
通过以上三种成分合理结合搭配，小猪血清细胞营养液在组织修复过程中科学地从细胞营养、生长、修复三方面对细胞进行全方位的维护和调节，达到缩短修复时间，加快皮肤修复的目的。
需要说明的是，在不冲突的情况下，本发明中的实施例及实施例中的特征可以相互组合。以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。

Claims (1)

1.一种小猪血清细胞营养液，其特征在于，包括小猪血清、表皮细胞生长因子和透明质酸；
各成分的体积百分比为：小猪血清：65-97％；表皮细胞生长因子：2-15％；透明质酸：1-30％。
CN201810610583.8A 2018-06-14 2018-06-14 一种小猪血清细胞营养液 Pending CN108635569A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810610583.8A CN108635569A (zh) 2018-06-14 2018-06-14 一种小猪血清细胞营养液

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810610583.8A CN108635569A (zh) 2018-06-14 2018-06-14 一种小猪血清细胞营养液

Publications (1)

Publication Number Publication Date
CN108635569A true CN108635569A (zh) 2018-10-12

Family

ID=63752443

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810610583.8A Pending CN108635569A (zh) 2018-06-14 2018-06-14 一种小猪血清细胞营养液

Country Status (1)

Country Link
CN (1) CN108635569A (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1700915A (zh) * 2002-08-23 2005-11-23 彼得·K·罗 生物的皮肤修复和增强
CN106727246A (zh) * 2017-02-08 2017-05-31 上海元茵生物科技有限公司 小牛血清细胞营养液

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1700915A (zh) * 2002-08-23 2005-11-23 彼得·K·罗 生物的皮肤修复和增强
US20060057119A1 (en) * 2002-08-23 2006-03-16 Law Peter K Biologic skin repair and enhancement
CN106727246A (zh) * 2017-02-08 2017-05-31 上海元茵生物科技有限公司 小牛血清细胞营养液

Similar Documents

Publication Publication Date Title
Michalopoulos Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas
Öztürk et al. Sulfated hydrogel matrices direct mitogenicity and maintenance of chondrocyte phenotype through activation of FGF signaling
Chen Extracellular matrix provides an optimal niche for the maintenance and propagation of mesenchymal stem cells
Bucci et al. Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity
Farwick et al. Fifty-kDa hyaluronic acid upregulates some epidermal genes without changing TNF-α expression in reconstituted epidermis
Vantler et al. PDGF-BB protects cardiomyocytes from apoptosis and improves contractile function of engineered heart tissue
Mariggiò et al. Enhancement of fibroblast proliferation, collagen biosynthesis and production of growth factors as a result of combining sodium hyaluronate and aminoacids
Bryant et al. Designing 3D photopolymer hydrogels to regulate biomechanical cues and tissue growth for cartilage tissue engineering
AR071479A1 (es) Hormona foliculo estimulante recombinante (rfsh) con union de acido sialico en a2,3 y a2,6
Joshi et al. Melatonin induces Nrf2‐HO‐1 reprogramming and corrections in hepatic core clock oscillations in non‐alcoholic fatty liver disease
AU2014248198B2 (en) Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators
Krishnan et al. In vitro mimics of bone remodeling and the vicious cycle of cancer in bone
MX339068B (es) Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
Shen et al. Physiological calcium combined with electrical pacing accelerates maturation of human engineered heart tissue
Lee et al. Stimulation of osteoblastic differentiation and mineralization in MC3T3-E1 cells by antler and fermented antler using Cordyceps militaris
BR112013012697A2 (pt) "método para diminuir expressão, produção ou secreção de um fator angiogênico ou fator hipertrófico ou ambos por células-tronco mesenquimais, métodos para diminuir um efeito inibidor, um efeito deletério, e um efeito de apoptose de células-tronco mesenquimais, método para aumentar um efeito estimulador de células-tronco mesenquimais, composição, e, método para preparar cartilagem em um indivíduo diagnosticado com cartilagem doente ou danificada."
Xu et al. Promotion of chondrogenic differentiation of mesenchymal stem cells by copper: Implications for new cartilage repair biomaterials
Nichol et al. Co-culture induces alignment in engineered cardiac constructs via MMP-2 expression
WO2006097701A3 (en) Skin equivalent culture
CN109529104A (zh) 促进细胞增殖迁移的凝胶敷料及其制备方法、使用方法
CN103385820A (zh) 一种修护眼霜
Lee et al. Fibromodulin modulates myoblast differentiation by controlling calcium channel
Li et al. Naturally derived injectable hydrogels with ROS-scavenging property to protect transplanted stem cell bioactivity for osteoarthritic cartilage repair
Wang et al. Stichopus japonicus polysaccharide stimulates osteoblast differentiation through activation of the bone morphogenetic protein pathway in MC3T3-E1 cells
Yamamoto et al. Potential of wound dressing composed of hyaluronic acid containing epidermal growth factor to enhance cytokine production by fibroblasts

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181012